| |
|
|
|
|
|
|
|||
|
Blood, 15 December 2005, Vol. 106, No. 13, pp. 4024.
ADAMTS13 and VWF: not just for TTP anymore?UNIVERSITY OF MICHIGAN
Shiga toxin stimulates VWF release from endothelial cells and impairs ADAMTS13-mediated VWF proteolysis, demonstrating potential roles for VWF and ADAMTS13 in hemolytic-uremic syndrome (HUS) pathogenesis.
In this issue of Blood, Nolasco and colleagues provide new evidence implicating VWF and ADAMTS13 in the pathogenesis of Shiga toxinmediated HUS. Using an elegant flow chamber system of cultured endothelial cells (both human umbilical vein endothelial cells [HUVECs] and human kidney glomerular microvascular endothelial cells [GMVECs]), the authors demonstrate that nanomolar concentrations of Shiga toxin stimulate the release of unusually large VWF (ULVWF) multimers, similar to the known endothelial cell agonist histamine. Furthermore, the authors go on to demonstrate that cleavage of ULVWF by ADAMTS13 is significantly impaired in the presence of Shiga toxin, suggesting a potential inhibitory role of this molecule in ADAMTS13-mediated VWF proteolysis. Thus, the authors hypothesize that Shiga toxinmediated ULVWF release and impairment of ADAMTS13 activity may promote platelet adhesion to glomerular endothelial cells, thereby contributing to the formation of the fibrin-rich thrombi seen in D+HUS.
It is becoming increasingly clear that the mechanism by which Shiga toxin induces the thrombotic events seen in HUS is multifactorial and involves more than just the direct toxic effects originally described for this molecule.2-4 For example, Shiga toxin renders cultured endothelial cells thrombogenic through the up-regulation of cell adhesion molecules, and induces the transcription of proinflammatory genes in endothelial cells and leukocytes.2,4 Whether the newly observed effects of Shiga toxin reported by Nolasco and colleagues play a role in the pathogenesis of D+HUS awaits further study. However, in support of this hypothesis, it recently has been demonstrated that Shiga toxin induces a TTP-like syndrome in ADAMTS13-deficient mice.5 Therefore, independent of its potential inhibitory role in ADAMTS13-mediated VWF proteolysis, Shiga toxin may indeed effect ULVWF release in vivo. Future work is sure to shed more light on the roles that Shiga toxin, VWF, and ADAMTS13 play in HUS, TTP, and other thrombotic microangiopathies. References
Related Article in Blood Online:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2005 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||